DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Jackisch C, Kim S, Semiglazov V et al.
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
Ann Oncol 2015;
26: 320-325
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.